Use of telehealth technology for home spirometry after lung transplantation: a randomized controlled trial

Hannover Medical School, Hannover, Germany.
Progress in transplantation (Aliso Viejo, Calif.) (Impact Factor: 0.69). 12/2010; 20(4):310-7. DOI: 10.7182/prtr.20.4.5522u13010202761
Source: PubMed

ABSTRACT Complications often occur during the early phase after lung transplantation, and rapid diagnosis is vital. Home spirometry is used to detect early changes in graft function. Bluetooth-equipped cell phones are easy to use and facilitate data transfer from home spirometry.
To explore use of home spirometry with Bluetooth data transfer in outpatient lung transplant recipients.
Single-center prospective randomized controlled trial. Intervention-Fifty-six patients were randomized either to home spirometry with data transfer via Bluetooth-equipped cell phones or to home spirometry alone before discharge after lung transplantation. In the Bluetooth group, results were transferred to a database capable of generating alarm messages.
Time from onset of symptoms to physician consultation during the first 6 months after lung transplantation was the primary end point.
Adherence to home spirometry was 97.2% in the Bluetooth group and 95.3% in the home spirometry alone group (P = .73). Median time to first consultation (P = .60) and frequency of consultation (P = .06) did not differ significantly in the 2 groups. Mean scores on the Hospital Anxiety and Depression Scale were lower in patients in the Bluetooth group (1.5; range, 0.0-4.0) than in the home spirometry alone group (4.0; range, 2.0-6.0; P = .04).
Home spirometry with data transfer is feasible and safe in lung transplant recipients. Compared with home spirometry alone, additional data transfer was equally effective regarding the time interval from symptom onset to consultation. Patients in the Bluetooth group reported less anxiety, which may improve emotional well-being.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Long-term lung transplant success is limited by bronchiolitis obliterans syndrome (BOS), a form of chronic allograft rejection that manifests in the majority of patients by five years post-transplant. Frequent monitoring of pulmonary function measurements through the use of daily home spirometry may have the capability to detect the onset of BOS sooner than standard pulmonary function testing. Early detection of BOS would confer a treatment advantage that may improve survival outcomes for lung transplant recipients. A systematic review of current evidence was used to determine the effectiveness of daily home spirometry as a BOS detection tool, in addition to its impact and survival outcomes. Articles were included in the present systematic review if they were randomized control studies and if their purpose(s) included investigation of spirometry as a BOS detection tool in lung transplant patients. A primary search of databases yielded 115 unique citations, with an additional four citations identified through a secondary review of the reference lists of retrieved articles. After application of all inclusion and exclusion criteria through abstract and full-text review, eight randomized controlled trials were included in the review. Forced expiratory volume in 1 s (FEV1) has been identified as the most reliable diagnostic tool for detecting the onset of BOS. Two studies compared the use of traditionally scheduled pulmonary function testing with daily home spirometry and found BOS stage 1 to appear 341 days earlier with home spirometry (P<0.001). Other studies that investigated the impact early detection had on survival showed a positive trend toward freedom from BOS and reduced rates of retransplantation, although these results did not reach statistical significance (P<0.07). Daily home spirometry has been shown to lead to earlier detection and staging of BOS when compared with standard pulmonary function testing. Although FEV1 has been shown to be the most sensitive and reliable marker of BOS onset, the impact of earlier staging via home spirometry on survival has not been reliably determined.
    Canadian Journal of Respiratory Therapy 01/2014; 50(1):17-22.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lung transplantation is the final treatment option in the end stage of certain lung diseases, once all possible conservative treatments have been exhausted. Depending on the indication for which lung transplantation is performed, it can improve the patient's quality of life (e.g., in emphysema) and/ or prolong life expectancy (e.g., in cystic fibrosis, pulmonary fibrosis, and pulmonary arterial hypertension). The main selection criteria for transplant candidates, aside from the underlying pulmonary or cardiopulmonary disease, are age, degree of mobility, nutritional and muscular condition, and concurrent extrapulmonary disease. The pool of willing organ donors is shrinking, and every sixth candidate for lung transplantation now dies while on the waiting list. We reviewed pertinent articles (up to October 2013) retrieved by a selective search in Medline and other German and international databases, including those of the International Society for Heart and Lung Transplantation (ISHLT), Eurotransplant, the German Institute for Applied Quality Promotion and Research in Health-Care (Institut für angewandte Qualitätsförderung und Forschung im Gesundheitswesen, AQUA-Institut), and the German Foundation for Organ Transplantation (Deutsche Stiftung Organtransplantation, DSO). The short- and long-term results have markedly improved in recent years: the 1-year survival rate has risen from 70.9% to 82.9%, and the 5-year survival rate from 46.9% to 59.6%. The 90-day mortality is 10.0%. The postoperative complications include acute (3.4%) and chronic (29.0%) transplant rejection, infections (38.0%), transplant failure (24.7%), airway complications (15.0%), malignant tumors (15.0%), cardiovascular events (10.9%), and other secondary extrapulmonary diseases (29.8%). Bilateral lung transplantation is superior to unilateral transplantation (5-year survival rate 57.3% versus 47.4%). Seamless integration of the various components of treatment will be essential for further improvements in outcome. In particular, the follow-up care of transplant recipients should always be provided in close cooperation with the transplant center.
    Deutsches Ärzteblatt International 02/2014; 111(7):107-16. DOI:10.3238/arztebl.2014.0107 · 3.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hintergrund Die Überwachung der Graft-Funktion meist durch Messung der Einsekundenkapazität (FEV1) hat einen besonders hohen Stellenwert, um nach der Lungentransplantation pathologische Veränderungen an der transplantierten Lunge zu erfassen. Ein Einsatzgebiet der Telemedizin ist die Erfassung, Kontrolle und Auswertung der Heimlungenfunktion. Fragestellung Einsatz und Effekte der telemedizinischen Kontrolle der Lungenfunktion nach Lungentransplantation und alternative Einsatzbereiche bei Lungentransplantation. Material und Methode Dieser Beitrag umfasst die Beschreibung, Auswertung und Diskussion von aktuellen Studien zur Telemedizin bei Lungentransplantation. Ergebnisse Neben dem Einsatz der Telemedizin zur Kontrolle der Heimlungenfunktion nach Lungentransplantation sind Studien zur Verbesserung der Therapietreue und zur Vernetzung von Transplantationszentrum und Patient vor Lungentransplantation unternommen worden. In allen Studien konnte gezeigt werden, dass die Akzeptanz der Telemedizin unter den Patienten sehr hoch ist und dem Patienten zusätzliche Sicherheit vermittelt. Insbesondere die grafische Auswertung von Parametern (z. B. FEV1) erweist sich als positiv. In Hinsicht auf eine frühere Erkennung von Abstoßungen oder Infekten durch die telemedizinische Kontrolle der Lungenfunktion konnte bislang kein Nutzen nachgewiesen werden. Schlussfolgerung Das Potential der telemedizinischen Überwachung von Patienten nach Lungentransplantation ist hoch, trotzdem wurden nur wenige Studien durchgeführt. Die Implementierung einer breiten telemedizinischen Versorgung der Patienten zur Verbesserung der Patientenversorgung und zur Kostenkontrolle stellt eine aktuelle Herausforderung für Transplantationszentren dar.
    Der Pneumologe 05/2014; 11(3):226-233. DOI:10.1007/s10405-013-0730-3